共 50 条
- [41] FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Migliorino, RitaLandi, LorenzaGaletta, DomenicoSoregaroli, DanielaRicciardi, SerenaMinuti, GabrieleMontrone, MicheleMarech, IlariaMorabito, AlessandroBerardi, RossanaNovello, SilviaRocco, DaniloPilotto, SaraZanelli, FrancescaBengala, CarmeloDelmonte, AngeloAieta, MicheleCortinovis, Diego LuigiCappuzzo, Federico
- [42] Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysisFRONTIERS IN IMMUNOLOGY, 2025, 16Liang, WeimingWang, ZhijingHuang, ZhilongHuang, YanpingLi, ChunyanLiang, YiwenHuang, MiaoyanZhang, DuoLi, Chenchen
- [43] Folgelinientherapie mit Cabozantinib bei lokal fortgeschrittenem oder metastasiertem Urothelkarzinom nach ImmuntherapieversagenCabozantinib bei Patienten mit lokal fortgeschrittenem oder metastasiertem Urothelzellkarzinom mit progredientem Verlauf nach Vortherapie mit einer Kombination aus platinbasierter Chemotherapie und PD-1/PD-L1-Inhibitoren oder Monotherapie mit PD-1/PD-L1-Inhibitoren (CabUC-Trial) – AB 66/18 der AUOFurther-line therapy with cabozantinib in locally advanced or metastasized urothelial carcinoma following failure of immunotherapyCabozantinib in patients with locally advanced or metastasized urothelial carcinoma with progression after pretreatment with a combination of platinum-based chemotherapy and PD-1/PD-L1 inhibitors or monotherapy with PD-1/PD-L1 inhibitors (CabUC trial)—AB 66/18 of the AUOForum, 2021, 36 (2) : 172 - 173H. RexerG. BartschC.-H. Ohlmann
- [44] Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lungJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Mu, FengchunFan, BingjieLi, HaoqianDong, TaotaoYao, YueyuanLi, ButuoJiang, ChaoWang, Linlin
- [45] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analysesANNALS OF ONCOLOGY, 2020, 31 : S558 - S559Lee, C-H.Shah, A. Y.Hsieh, J. J.Rao, A.Pinto, A.Bilen, M. A.Cohn, A. L.Di Simone, C.Shaffer, D. R.Girones Sarrio, R.Ribe, S. GunnestadWu, J.Schmidt, E.Kubiak, P.Okpara, C. E.Smith, A. D.Motzer, R. J.
- [46] Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two casesFRONTIERS IN IMMUNOLOGY, 2022, 13Shang, LinLi, PengFan, JieZhao, ChunningNiu, XiangyingBian, QitianYuan, ZhilinKong, YanlongZhu, TingshunXu, BinDong, JianxinXiang, Hongjun
- [47] Re: Health-related Quality of Life of Patients With Locally Advanced or Metastatic Urothelial Cancer Treated With Enfortumab Vedotin After Platinum and PD-1/PD-L1 Inhibitor Therapy: Results From Cohort 1 of the Phase 2 EV-201 Clinical Trial Editorial CommentJOURNAL OF UROLOGY, 2023, 210 (01): : 218 - 218Chang, Sam S.McGregor, B.O'Donnell, P. H.Balar, A.
- [48] A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinomaEUROPEAN UROLOGY, 2021, 79 : S933 - S933Shi, Y.An, X.Yan, R.Yao, K.Xue, C.Guo, S.Liu, T.Li, J.Ma, H.Tian, L.Zhou, F.Shi, Y.Han, H.
- [49] First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+locally advanced or metastatic urothelial carcinoma (UC) in Asian patientsANNALS OF ONCOLOGY, 2019, 30 : 367 - 367Ye, D.Liu, J.Zhou, A.Zou, Q.Li, H.Fu, C.Hu, H.Huang, J.Zhu, S.Jin, J.Ma, L.Guo, J.Xiao, J.Park, S. H.Zhang, D.Qiu, X.Bao, Y.Zhang, L.Shen, W.Feng, B.
- [50] PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Lo Russo, GiuseppeGanzinelli, MonicaSgambelluri, FrancescoGalli, FrancescaPrelaj, ArselaManglaviti, SaraBottiglieri, AchilleDi Mauro, Rosa MariaFerrara, RobertoDumitrascu, Andra DianaSottotetti, ElisaMartinetti, AntoniaFabbri, AlessandraRulli, ElianaDe Braud, Filippo G.Torri, ValterGarassino, Marina ChiaraAnichini, AndreaProto, ClaudiaMortarini, Roberta